Patritumab Deruxtecan
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Colorectal Cancer
Conditions
Metastatic Colorectal Cancer
Trial Timeline
Sep 14, 2020 → Feb 3, 2022
NCT ID
NCT04479436About Patritumab Deruxtecan
Patritumab Deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Metastatic Colorectal Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04479436. Target conditions include Metastatic Colorectal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05620914 | Phase 2 | Withdrawn |
| NCT06941272 | Phase 1/2 | Recruiting |
| NCT06596694 | Phase 1/2 | Recruiting |
| NCT05865990 | Phase 2 | Active |
| NCT04479436 | Phase 2 | Terminated |
| NCT02980341 | Phase 1/2 | Completed |
Competing Products
20 competing products in Metastatic Colorectal Cancer